I. Patients and &. , 81 II-1. Patients 81 II-2, II-2-6. Tests statistiques, pp.83-85

. Le, TCZ a été instauré à la dose de 8 mg/kg pour la totalité des patients, pp.15-2941

. En-moyenne, 94 anti-TNF-! : 10 patients (19,61%) avaient été traités par 1 anti-TNF-!, 24 par 2 anti-TNF-!, 06&) et 10 par 3 anti-TNF-!, p.61

I. Ghozlani, L. Achemlal, and A. Rezqi, Physiopathologie de la polyarthrite rhumatoïde, Rev Mar Rhum, vol.19, pp.6-9, 2012.

J. Morel, P. Miossec, and B. Combe, Immunopathologie de la polyarthrite rhumatoïde, EMC Rhumatologie Orthopédie, pp.218-230, 2004.

A. Constantin and A. Cantagrel, Membrane synoviale : des conditions physiologiques à l’inflammation de la polyarthrite rhumatoïde. Implications thérapeutiques, 2013.

L. Guglielmi, Les cytokines et leurs récepteurs Master 1 Biologie Santé, faculté de médecine, Cytokines.pdf, 2013.

E. Bettelli, Y. Carrier, and W. Gao, Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells, Nature, vol.31, issue.7090, pp.235-243, 2006.
DOI : 10.1038/nature04753

E. Assier, M. C. Boissier, and J. M. Dayer, Interleukine-6 : de la d??couverte de la cytokine au d??veloppement d???un traitement cibl??, Revue du Rhumatisme, vol.77, pp.316-338, 2010.
DOI : 10.1016/S1169-8330(10)70004-1

L. Yeo, K. M. Toellner, and M. Salmon, Cytokine mRNA profiling identifies B cells as a major source of RANKL in rheumatoid arthritis, Annals of the Rheumatic Diseases, vol.70, issue.11, pp.2022-2030, 2011.
DOI : 10.1136/ard.2011.153312

R. Bedel, C. Borg, and J. Wijdenes, Rationnel de l'utilisation thérapeutique du blocage de l'interleukine-6. Réflexions rhumatologiques, pp.179-182, 2009.

G. Fantuzzi, Adipose tissue, adipokines, and inflammation, Journal of Allergy and Clinical Immunology, vol.115, issue.5, pp.911-920, 2005.
DOI : 10.1016/j.jaci.2005.02.023

P. C. Heinrich, I. Behrmann, and G. Müller-newen, Interleukin-6-type cytokine signalling through the gp130, Jak/STAT pathway. Biochem J, vol.334, pp.97-314, 1998.

C. Chung, J. Liao, and B. Liu, Specific Inhibition of Stat3 Signal Transduction by PIAS3, Science, vol.278, issue.5344, pp.1803-1808, 1997.
DOI : 10.1126/science.278.5344.1803

P. Voulgari, G. Kolios, and G. Papadopoulos, Role of Cytokines in the Pathogenesis of Anemia of Chronic Disease in Rheumatoid Arthritis, Clinical Immunology, vol.92, issue.2, pp.153-60, 1999.
DOI : 10.1006/clim.1999.4736

N. Sattar, D. Mccarey, and H. Capell, Explaining How "High-Grade" Systemic Inflammation Accelerates Vascular Risk in Rheumatoid Arthritis, Circulation, vol.108, issue.24, pp.2957-63, 2003.
DOI : 10.1161/01.CIR.0000099844.31524.05

D. P. Ramji, A. Vitelli, and F. Tronche, The two C/EBP isoforms, IL6DBP/NFIL6 and CEBP6??/NFIL63, are induced by IL6?? to promote acute phase gene transcription via different mechanisms, Nucleic Acids Research, vol.21, issue.2, pp.289-94, 1993.
DOI : 10.1093/nar/21.2.289

T. Hirano, T. Matsuda, and M. Turner, Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis, European Journal of Immunology, vol.73, issue.11, pp.1797-801, 1988.
DOI : 10.1002/eji.1830181122

M. Kopf, H. Baumann, and G. Freer, Impaired immune and acute-phase responses in interleukin-6-deficient mice, Nature, vol.368, issue.6469, pp.339-381, 1994.
DOI : 10.1038/368339a0

M. W. Nijsten, D. Groot, E. R. , T. Duis, and H. J. , SERUM LEVELS OF INTERLEUKIN-6 AND ACUTE PHASE RESPONSES, The Lancet, vol.330, issue.8564, p.921, 1987.
DOI : 10.1016/S0140-6736(87)91413-9

P. E. Lipsky, Interleukin-6 and rheumatic diseases, Arthritis Research & Therapy, vol.8, issue.Suppl 2, p.4, 2006.
DOI : 10.1186/ar1918

C. Gabay, Interleukin-6 and chronic inflammation, Arthritis Research & Therapy, vol.8, issue.Suppl 2, p.3, 2006.
DOI : 10.1186/ar1917

R. L. Jilka, G. Hangoc, and G. Girasole, Increased osteoclast development after estrogen loss: mediation by interleukin-6, Science, vol.257, issue.5066, pp.88-91, 1992.
DOI : 10.1126/science.1621100

D. Benedetti, F. Rucci, N. , D. Fattore, and A. , Impaired skeletal development in interleukin-6???transgenic mice: A model for the impact of chronic inflammation on the growing skeletal system, Arthritis & Rheumatism, vol.50, issue.11, pp.3551-63, 2006.
DOI : 10.1002/art.22175

L. Goff, B. Blanchard, F. Berthelot, and J. M. , R??le de l???interleukine-6??dans les destructions ost??oarticulaires et la perte osseuse syst??mique au cours de la polyarthrite rhumato??de, Revue du Rhumatisme, vol.77, issue.3, pp.233-238, 2010.
DOI : 10.1016/j.rhum.2009.10.033

P. K. Wong, I. K. Campbell, and P. J. Egan, The role of the interleukin-6 family of cytokines in inflammatory arthritis and bone turnover, Arthritis & Rheumatism, vol.276, issue.5, pp.1177-89, 2003.
DOI : 10.1002/art.10943

C. Han, M. U. Rahman, and M. K. Doyle, Association of anemia and physical disability among patients with rheumatoid arthritis, J Rheumatol, vol.34, pp.2177-82, 2007.

G. Grunfeld and M. A. Palladino, Tumor necrosis factor: immunologic, antitumor, metabolic and cardiovascular activities, Adv Intern Med, vol.35, pp.45-72, 1990.

D. Coyral and P. Bertin, Prise en charge actuelle de la polyarthrite rhumatoïde, Actualités Pharmaceutiques, vol.430, p.16, 2004.

E. T. Molenaar, A. E. Voskuyl, and H. J. Dinant, Progression of radiologic damage in patients with rheumatoid arthritis in clinical remission, Arthritis & Rheumatism, vol.46, issue.1, pp.36-42, 2004.
DOI : 10.1002/art.11481

B. Combe, Polyarthrite rhumatoïde de l’adulte : clinique et diagnostic. EMC-Appareil Locomoteur, pp.1-17, 2007.
DOI : 10.1016/s0246-0521(07)43710-x

G. Tenga, La polyarthrite rhumatoïde : une pathologie évolutive invalidante. Moniteur hospitalier, p.200, 2007.

J. Morel and B. Combe, How to predict prognosis in early rheumatoid arthritis, Best Practice & Research Clinical Rheumatology, vol.19, issue.1, pp.137-183, 2005.
DOI : 10.1016/j.berh.2004.08.008

B. Combe, R. Landewe, and C. Lukas, EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT), Annals of the Rheumatic Diseases, vol.66, issue.1, pp.34-45, 2007.
DOI : 10.1136/ard.2005.044354

T. Pham, B. Fautrel, . Gossecl, B. Combe, R. Flipo et al., Physical examination and laboratory tests in the management of patients with rheumatoid arthritis: development of recommendations for clinical practice based on published evidence and expert opinion, Joint Bone Spine, vol.72, issue.3, pp.222-230, 2005.
DOI : 10.1016/j.jbspin.2004.10.010

R. B. Landewe, M. Boers, and A. C. Verhoeven, COBRA combination therapy in patients with early rheumatoid arthritis: Long-term structural benefits of a brief intervention, Arthritis & Rheumatism, vol.343, issue.Suppl, pp.347-56, 2002.
DOI : 10.1002/art.10083

M. Korpela, L. Laasonen, and P. Hannonen, Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs: Five-year experience from the FIN-RACo study, Arthritis & Rheumatism, vol.43, issue.Suppl, pp.2072-81, 2004.
DOI : 10.1002/art.20351

J. S. Smolen, R. Landewé, F. C. Breedveld, M. Dougados, and P. Emery, EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs, Annals of the Rheumatic Diseases, vol.69, issue.6, 2010.
DOI : 10.1136/ard.2009.126532

A. European-medicines, Résumé des Caractéristiques du Produit méthotrexate, 2012.

H. A. Capell, R. Madhoc, and J. A. Hunter, Lack of radiological and clinical benefit over two years of low dose prednisolone for rheumatoid arthritis: results of a randomised controlled trial, Annals of the Rheumatic Diseases, vol.63, issue.7, pp.797-803, 2004.
DOI : 10.1136/ard.2003.014050

B. Svensson, A. Boonen, K. Albertsson, D. Van-der-heijde, and I. Hafström, Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: A two-year randomized trial, Arthritis & Rheumatism, vol.51, issue.11, pp.3360-70, 2005.
DOI : 10.1002/art.21298

J. Kirwan, Effects of glucocorticoids on radiological progression in rheumatoid arthritis, Cochrane Libr, vol.19, issue.1, p.6356, 2007.
DOI : 10.1002/14651858.CD006356

A. Van-everdingen, The clinical effect of glucocorticoids in patients with rheumatoid arthritis may be masked by decreased use of additional therapies, Arthritis Care & Research, vol.43, issue.Suppl 9, pp.233-238, 2004.
DOI : 10.1002/art.20251

P. Tugwell, T. Pincus, and D. Yocum, Combination Therapy with Cyclosporine and Methotrexate in Severe Rheumatoid Arthritis, New England Journal of Medicine, vol.333, issue.3, pp.137-141, 1995.
DOI : 10.1056/NEJM199507203330301

V. Strand, S. Cohen, and M. Schiff, Treatment of Active Rheumatoid Arthritis With Leflunomide Compared With Placebo and Methotrexate, Archives of Internal Medicine, vol.159, issue.21, pp.2542-2550, 1999.
DOI : 10.1001/archinte.159.21.2542

J. Braun, Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: Results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial, Arthritis & Rheumatism, vol.64, issue.1, pp.73-81, 2008.
DOI : 10.1002/art.23144

M. E. Suarez-almazor, E. Belek, and B. Shea, Methotrexate for treating rheumatoid arthritis (Cochrane Review) The Cochrane Library, 2001.

D. E. Furst, N. Erikson, and L. Clute, Adverse experience with methotrexate during 176 weeks of a longterm prospective trial in patients with rheumatoid arthritis, J Rheumatol, vol.17, pp.1628-1635, 1990.

P. Emery, F. C. Breedveld, and E. M. Lemmel, A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis, Rheumatology, vol.39, issue.6, pp.655-665, 2000.
DOI : 10.1093/rheumatology/39.6.655

F. Sanguinet, S. Neveu, C. Richez, and T. , Évaluation de l’efficacité clinique et radiologique du méthotrexate, en monothérapie, chez des patients atteints d’une polyarthrite rhumatoïde (PR) et naïfs de méthotrexate, 2009.

J. M. Bathon, R. W. Martin, and R. M. Fleixchmann, A Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid Arthritis, New England Journal of Medicine, vol.343, issue.22, pp.1586-1593, 2000.
DOI : 10.1056/NEJM200011303432201

F. Breedveld, A. F. Kavanaugh, and S. B. Cohen, Early treatment of Rheumatoid Arthritis with adalimumab plus methotrexate vs adalimumab alone or methotrexate alone: the PREMIER study, Arthritis Rheum, vol.50, p.4096, 2004.

J. Kremer, M. Genovese, and G. W. Cannon, Combination leflunomide and methotrexate (MTX) therapy for patients with active rheumatoid arthritis failing MTX monotherapy: open-label extension of a randomized, double-blind, placebo controlled trial, J Rheumatol, vol.31, pp.1521-1531, 2004.

A. Perdriger and B. Combe, Le léflunomide: mise au point sur son utilisation actuelle, p.312, 2005.

D. Van-der-heijde, L. Klareskog, and V. Rodriguez-valverde, Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: Two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial, Arthritis & Rheumatism, vol.47, issue.4, pp.1063-74, 2006.
DOI : 10.1002/art.21655

F. C. Breedveld, M. H. Weisman, and A. F. Kavanaugh, The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment, Arthritis & Rheumatism, vol.39, issue.1, pp.26-37, 2006.
DOI : 10.1002/art.21519

S. Clair, E. Van-der-heijde, D. Smolen, and J. , Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: A randomized, controlled trial, Arthritis & Rheumatism, vol.48, issue.11, pp.3432-3475, 2004.
DOI : 10.1002/art.20568

X. Mariette, D. Cazals-hatem, J. Warszawki, and F. Liote, Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France, Blood, vol.99, issue.11, pp.3909-3915, 2002.
DOI : 10.1182/blood.V99.11.3909

S. Cohen, G. Cannon, and M. Schiff, Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate, Arthritis & Rheumatism, vol.353, issue.9, pp.1984-92, 2001.
DOI : 10.1002/1529-0131(200109)44:9<1984::AID-ART346>3.0.CO;2-B

E. Li, L. S. Tam, and B. Tomlinson, Leflunomide in the treatment of rheumatoid arthritis, Clinical Therapeutics, vol.26, issue.4, pp.447-459, 2004.
DOI : 10.1016/S0149-2918(04)90048-3

J. Smolen, P. Emery, and J. Kalden, The efficacy of leflunomide monotherapy in rheumatoid arthritis: towards the goals of disease modifying antirheumatic drug therapy, J Rheumatol, vol.71, pp.13-20, 2004.

J. Sharp, V. Strand, and H. Leung, Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: Results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis, Arthritis & Rheumatism, vol.43, issue.3, pp.495-505, 2000.
DOI : 10.1002/1529-0131(200003)43:3<495::AID-ANR4>3.0.CO;2-U

D. L. Scott, J. S. Smolen, and J. R. Kalden, Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine, Annals of the Rheumatic Diseases, vol.60, issue.10, pp.913-923, 2001.
DOI : 10.1136/ard.60.10.913

P. Emery, F. Breedveld, and E. Lemmel, A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis, Rheumatology, vol.39, issue.6, pp.655-665, 2000.
DOI : 10.1093/rheumatology/39.6.655

J. Kalden, C. Antoni, and J. Alvaro-gracia, The use of combination of leflunomide with biological agents in the treatment of rheumatoid arthritis, Journal of Rheumatology, vol.32, pp.1620-1631, 2005.

A. Finckh, S. Dehler, and C. Gabay, The effectiveness of leflunomide as a co-therapy of tumour necrosis factor inhibitors in rheumatoid arthritis: a population-based study, Annals of the Rheumatic Diseases, vol.68, issue.1, pp.33-39, 2009.
DOI : 10.1136/ard.2007.085696

B. Macconkey, R. Amos, and E. Butler, Salazopyrine in rheumatoid arthritis, Agent Actions, vol.8, pp.226-231, 1978.

S. Clair, E. Van-der-heijde, D. Smolen, and J. , Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: A randomized, controlled trial, Arthritis & Rheumatism, vol.48, issue.11, pp.3432-3475, 2004.
DOI : 10.1002/art.20568

D. Van-der-heijde, L. Klareskog, and V. Rodriguez-valverde, Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: Two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial, Arthritis & Rheumatism, vol.47, issue.4, pp.1063-74, 2006.
DOI : 10.1002/art.21655

D. Furst, M. Schiff, and R. Fleischmann, Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis), J Rheumatol, vol.30, pp.2563-2571, 2003.

A. Finckh, J. F. Simard, C. Gabay, and P. Guerne, Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis, Annals of the Rheumatic Diseases, vol.65, issue.6, pp.746-52, 2006.
DOI : 10.1136/ard.2005.045062

O. Brocq, Y. Plubel, and V. Breuil, Etanercept – infliximab switch in rheumatoid arthritis 14 out of 131 patients treated with anti-TNFalpha, Presse Med, vol.31, pp.1836-1845, 2002.

H. Autorité-de-santé and . Roactemra, Avis de la Commission de transparence, 2009. www.has-sante.fr/portail/jcms/c_854698, p.635205, 2013.

F. Tubach, D. Salmon, P. Ravaud, and Y. Allanore, Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective french research axed on tolerance of biotherapies registry, Arthritis & Rheumatism, vol.18, issue.7, pp.1884-94, 2009.
DOI : 10.1002/art.24632

URL : https://hal.archives-ouvertes.fr/inserm-00400633

L. Carmona, J. Gomez-reino, and V. Rodriguez-valverde, Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists, Arthritis & Rheumatism, vol.75, issue.6, pp.1766-72, 2005.
DOI : 10.1002/art.21043

S. Setoguchi, D. H. Solomon, and M. E. Weinblatt, Tumor necrosis factor ?? antagonist use and cancer in patients with rheumatoid arthritis, Arthritis & Rheumatism, vol.14, issue.9, pp.2757-64, 2006.
DOI : 10.1002/art.22056

F. Wolfe and K. Michaud, The effect of methotrexate and anti???tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 PERSON-YEARS of observation, Arthritis & Rheumatism, vol.52, issue.5, pp.1433-1442, 2007.
DOI : 10.1002/art.22579

X. Mariette, F. Tubach, and P. Ravaud, Patients on anti-TNF have an increased risk of lymphoma compared to the general population. Results of the French-year prospective Ratio observatory, Ann Rheum Dis, vol.67, p.323, 2008.

R. Nixon, B. Bansback, and A. Brennan, The efficacy of inhibiting tumour necrosis factor ?? and interleukin 1 in patients with rheumatoid arthritis: a meta-analysis and adjusted indirect comparisons, Rheumatology, vol.46, issue.7, pp.1140-1147, 2007.
DOI : 10.1093/rheumatology/kem072

R. Fleischmann, R. Stern, and I. Iqbal, Anakinra: an inhibitor of IL-1 for the treatment of rheumatoid arthritis, Expert Opinion on Biological Therapy, vol.3, issue.3, pp.1333-1344, 2004.
DOI : 10.1093/rheumatology/keh140

P. Emery, R. Fleischmann, and A. Filipowicz-sosnowska, The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial, Arthritis & Rheumatism, vol.31, issue.5, pp.1390-400, 2006.
DOI : 10.1002/art.21778

J. Smolen, E. Keystone, P. Emery, and F. Breedveld, Consensus statement on the use of rituximab in patients with rheumatoid arthritis, Annals of the Rheumatic Diseases, vol.66, issue.2, pp.143-50, 2007.
DOI : 10.1136/ard.2006.061002

J. Sibilia, J. Gottenberg, and X. Mariette, Le rituximab??: une nouvelle possibilit?? th??rapeutique dans la polyarthrite rhumato??de, Revue du Rhumatisme, vol.75, issue.9, pp.782-789, 2008.
DOI : 10.1016/j.rhum.2008.02.013

H. Autorité and D. Santé, Polyarthrite rhumatoïde : diagnostic et prise en charge initiale. Synthèse des recommandations, pp.2-9, 2007.

H. Autorité and D. Santé, Polyarthrite rhumatoïde : diagnostic et prise en charge initiale.Synthèse des recommandations, pp.2-9, 2007.

I. Catala and C. Desmoulins, ADACTA : première comparaison directe anti IL6-anti TNF en monothérapie dans la PR. 8 juin 2012, p.5, 2013.

M. Schiff, Abatacept SC versus adalimumab on background methotrexate in RA: one year results from the AMPLE study. Oral presentation 0022, 2012.

E. Toussirot, Blocage de l’interleukine-6 dans la polyarthrite rhumatoïde. Résultats des essais cliniques. Réflexions rhumatologiques, pp.187-192, 2009.

G. Bergman, M. Hochberg, and M. Boers, Indirect Comparison of Tocilizumab and Other Biologic Agents in Patients with Rheumatoid Arthritis and Inadequate Response to Disease-Modifying Antirheumatic Drugs, Seminars in Arthritis and Rheumatism, vol.39, issue.6, pp.425-466, 2010.
DOI : 10.1016/j.semarthrit.2009.12.002

N. Nishimoto, K. Terao, T. Mima, H. Nakahara, N. Takagi et al., Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease, Blood, vol.112, issue.10, pp.3959-64, 2008.
DOI : 10.1182/blood-2008-05-155846

R. Van-vollenhoven, N. Nishimoto, and H. Yamanaka, Experience with mycobacterium tuberculosis infection reported in the tocilizumab worldwide RA safety database, Ann Rheum Dis, vol.68, issue.suppl3, p.567, 2009.

N. Nishimoto, N. Miyasaka, K. Yamamoto, S. Kawai, T. Takeuchi et al., Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study, Annals of the Rheumatic Diseases, vol.68, issue.10, pp.1580-1584, 2009.
DOI : 10.1136/ard.2008.092866

R. Van-vollenhoven, D. Siri, and R. Furie, Long-term safety and tolerability of tocilizumab treatment in patients with rheumatoid arthritis and mean treatment duration of 2,4 years, Arthritis rheumatoid, vol.60, p.731, 2009.

N. Nishimoto, K. Yoshizaki, K. Maeda, and . Toxicity, pharmacokinetics and dose finding study of repetitive treatment with the humanized anti-intereukin-6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical study, J Rheumatol, vol.30, pp.1426-1461, 2003.

E. Choy, D. Isenberg, and T. Garrood, Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: A randomized, double-blind, placebo-controlled, dose-escalation trial, Arthritis & Rheumatism, vol.31, issue.12, pp.3143-50, 2002.
DOI : 10.1002/art.10623

G. Jones, A. Sebba, and J. Gu, Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study, Annals of the Rheumatic Diseases, vol.69, issue.01, pp.88-96, 2010.
DOI : 10.1136/ard.2008.105197

J. Smolen, A. Beaulieu, and A. Rubbert-roth, Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial, The Lancet, vol.371, issue.9617, pp.987-97, 2008.
DOI : 10.1016/S0140-6736(08)60453-5

J. Kremer, R. Fleischmann, and A. Halland, Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with an inadequate response to methotrexate: the LITHE study, European Musculoskeletal Review, vol.7, issue.2, pp.108-119, 2012.

M. Genovese, J. Mckay, and E. Nasonov, Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study, Arthritis & Rheumatism, vol.63, issue.2, pp.2968-80, 2008.
DOI : 10.1002/art.23940

P. Emery, E. Keystone, and H. Tony, IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial, Annals of the Rheumatic Diseases, vol.67, issue.11, pp.1516-1539, 2008.
DOI : 10.1136/ard.2008.092932

Y. Yazici, J. Curtis, A. Ince, H. Baraf, R. Malamet et al., Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study, Annals of the Rheumatic Diseases, vol.71, issue.2, pp.198-205, 2012.
DOI : 10.1136/ard.2010.148700

V. Bykerk, Tocilizumab in patients with active rheumatoid arthritis and inadequate responses to DMARDs and/or TNF inhibitors: a large, open-label study close to clinical practice, Annals of the Rheumatic Diseases, vol.71, issue.12
DOI : 10.1136/annrheumdis-2011-201087

G. Burmester, E. Feist, and H. Kellner, Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA), Annals of the Rheumatic Diseases, vol.70, issue.5, pp.755-764, 2011.
DOI : 10.1136/ard.2010.139725

R. N. Maini, P. C. Taylor, and J. Szechinski, Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate, Arthritis & Rheumatism, vol.279, issue.9, pp.2817-2846, 2006.
DOI : 10.1002/art.22033

T. Takeuchi, Y. Tanaka, and K. Amano, Clinical, radiographic and functional effectiveness of tocilizumab for rheumatoid arthritis patients--REACTION 52-week study, Rheumatology, vol.50, issue.10, pp.1908-1923, 2011.
DOI : 10.1093/rheumatology/ker221

M. Dougados, K. Kissel, and T. Sheeran, Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY), Annals of the Rheumatic Diseases, vol.72, issue.1, pp.2011-201282
DOI : 10.1136/annrheumdis-2011-201282

Y. Nakashima, M. Kondo, and H. Harada, Clinical evaluation of tocilizumab for patients with active rheumatoid arthritis refractory to anti-TNF biologics: tocilizumab in combination with methotrexate, Modern Rheumatology, vol.69, issue.4, pp.343-52, 2010.
DOI : 10.1136/ard.2006.068064

M. Genovese, J. D. Mckay, and E. L. Nasonov, Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study, Arthritis & Rheumatism, vol.63, issue.2, p.2968, 2008.
DOI : 10.1002/art.23940

J. S. Smolen, A. D. Beaulieu, and A. Dirranian, Safety of tocilizumab in patients with rheumatoid arthritis: pooled analysis of five phase III clinical trials, Arthritis Rheum, vol.58, p.784, 2008.

K. Yoshida, Y. Tokuda, and K. Hosaka, Drug survival and safety of tocilizumab in comparison to TNF inhibitors including use as second biologic agent, 2010.

L. Campbell, C. Chen, and R. Parker, Risk of adverse events including serious infections in rheumatoid arthritis patients treatedwith tocilizumab : a systematic literature review and meta-analysis of randomised trials, 2010.

N. Nishimoto, K. Ito, and N. Takagi, Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensions, Modern Rheumatology, vol.58, issue.10, p.222, 2010.
DOI : 10.3109/s10165-008-0111-7

M. Genovese, A. Sebba, and A. Ruppert-roth, Safety and tolerability of tocilizumab in long-term extension studies of rheumatoid arthritis, Presented at the Annual Scientific Meeting of the American College of Rheumatology, 2010.

M. M. An, Z. Zou, and H. Shen, The addition of tocilizumab to DMARD therapy for rheumatoid arthritis: a meta-analysis of randomized controlled trials, European Journal of Clinical Pharmacology, vol.309, issue.Suppl 3, p.49, 2010.
DOI : 10.1007/s00228-009-0754-0

M. Aarat, . Patel, W. Larry, and . Moreland, Interleukin-6 inhibition for treatment of rheumatoid arthritis: A review of tocilizumab therapy, Drug Des Devel Ther, vol.4, pp.263-278, 2010.

M. Genovese, J. Smolen, and P. Emery, Lipid and inflammatory biomarker profiles in patients receiving tocilizumab for rheumatoid arthritis: Analysis for five 3 clinical trials, Arthritis Rheum, vol.58, p.331, 2008.

V. Oldfield, S. Dhillon, and G. L. Plosker, Tocilizumab, Drugs, vol.45, issue.6, p.609, 2009.
DOI : 10.2165/00003495-200969050-00007

K. Kume, K. Amano, and S. Yamada, Tocilizumab improves arterial stiffness compared with others biologics in rheumatoid arthritis. Open label randomized cohort study, 2010.

I. Mcinnes, J. S. Lee, and J. Giles, Lipid and inflammation parameters : A translational, randomized placebo-controlled study to evaluate effect of Tocilizumab: The MEASURE Study, 2010.

B. Hansel and E. Bruckert, Profil lipidique et risque cardiovasculaire chez les patients atteints de polyarthrite rhumato??de??: influence de la maladie et de la th??rapeutique m??dicamenteuse, Annales d'Endocrinologie, vol.71, issue.4, p.257, 2010.
DOI : 10.1016/j.ando.2010.03.005